Antipsychotics to Drive the US Generics Market

The US generics market has been effectively growing at a rapid pace for the past few years as blockbuster drugs are losing their patents and the government is making efforts to provide cheap medicines to the population. In 2010, the market was estimated to cross US$ 80 Billion mark, growing at the rate of around 10% over 2009. Regulatory environment also play an important role in strengthening the market potential and there are certain acts and programs that support the initiative. As far as the government’s role and other key segments are concerned, our new report “Booming US Generic Drug Market” provides an in-depth analysis and investigation.

 

The report finds out that, substantial growth in antipsychotics generic drugs are likely to be the next key development in the US generics market. Patent expiration of Seroquel and Zyprexa will propel the level of competition among generic players and the market will receive a strong growth momentum. Moreover, players’ focus to manufacture low cost drugs will act as a major growth contributor.

 

The report “Booming US Generic Drug Market” presents the overall US generics market in an effective manner and broadly evaluates the current trends and their impact on the industry revenue. Under the regulatory environment, several key initiatives of the US government towards generics is outlined and discussed. These acts are important for clients to know as they depict the role of respective authorities in making viable laws.

 

The report is an outcome of an extensive research and prudent analysis of the US generics market that provides reliable statistics and proper content flow. Forecasting in the report makes use of effective methods and techniques so that outlook may be realistic in nature. The description and key activities of active market players further enrich clients with information related to private sector participation.

For more information visit: http://www.rncos.com/Report/IM589.htm